Denosumab use on the rise

Around half of all people starting osteoporosis therapy for the first time in 2015 were prescribed denosumab, according to PBAC figures that also show a large number of people switching to denosumab from other medicines.

The figures also show that a decline in the use of osteoporosis drugs has been arrested. The previous decline was probably due to widely publicised health concerns including rare incidents of osteonecrosis of the jaw associated with bisphosphonate use.